Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06444815 · ClinicalTrials.gov registry record · Phase 1

A Study of VET3-TGI in Patients With Solid Tumors

A Phase 1 study of Non-Small Cell Lung Cancer and Cervical Cancer, sponsored by KaliVir Immunotherapeutics.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
7
Study locations

NCT06444815 is a Phase 1 study of Non-Small Cell Lung Cancer and Cervical Cancer that is actively recruiting participants, run by KaliVir Immunotherapeutics. The registered enrollment target is 60 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06444815, a Phase 1 study of Non-Small Cell Lung Cancer and Cervical Cancer, is actively recruiting participants, sponsored by KaliVir Immunotherapeutics.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
7
Study locations

Study Summary

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).

Conditions Studied

Non-Small Cell Lung Cancer Cervical Cancer Head and Neck Squamous Cell Carcinoma Renal Cell Carcinoma Solid Tumor, Adult Kidney Cancer Mesothelioma Melanoma Stage IV Microsatellite Stable Colorectal Cancer Merkel Cell Carcinoma of Skin

Interventions

  • DRUG Pembrolizumab
  • DRUG VET3-TGI

Study Locations (7)

California

  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • UC Irvine Health - Orange

Texas

  • Mary Crowley Cancer Research - Dallas
  • University of Texas MD Anderson Cancer Center - Houston

Florida

  • University of Miami - Miami

Indiana

  • Community Health Network - Indianapolis

Pennsylvania

  • UPMC- Hillman Cancer Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-09-16
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

KaliVir Immunotherapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06444815

The ClinicalTrials.gov registry entry for NCT06444815 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is KaliVir Immunotherapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06444815 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT06444815 about?

NCT06444815 is a clinical study titled "A Study of VET3-TGI in Patients With Solid Tumors". VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when...

What is the current status of trial NCT06444815?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-09-16. Estimated completion is 2027-12-31.

What conditions does trial NCT06444815 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Solid Tumor, Adult.

What interventions are being tested in trial NCT06444815?

The interventions under investigation include: Pembrolizumab (DRUG), VET3-TGI (DRUG).

Who is sponsoring clinical trial NCT06444815?

This trial is sponsored by KaliVir Immunotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06444815 being conducted?

This trial has 7 study locations across California, Florida, Indiana, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Cervical Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.